| Similar Articles |
|---|
 |
The Motley Fool
September 5, 2007
Brian Lawler |
Not Your Typical Product Recall Shire and Noven will fix an annoying foible of their ADHD patch, Daytrana, making the back adhesive easier to unpeel.   |
The Motley Fool
May 1, 2007
Brian Lawler |
Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up. |
The Motley Fool
December 5, 2005
W.D. Crotty |
Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings. |
The Motley Fool
July 12, 2007
Brian Lawler |
Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
December 28, 2007
Brian Lawler |
Investors Wary on Noven Approval Noven Pharmaceuticals announces that the FDA has issued a tentative approval for one of its drugs, yet shares are trading lower since the news. Is the "tentative" status making investors jittery? |
The Motley Fool
June 30, 2008
Brian Orelli |
Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults. |
The Motley Fool
July 27, 2007 |
Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs. |
The Motley Fool
December 26, 2006
Brian Lawler |
Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich. |
The Motley Fool
October 9, 2006
Brian Lawler |
New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up. |
BusinessWeek
October 24, 2005
Gene G. Marcial |
Undivided Attention For An ADHD Battle Sales of Shire Pharmaceuticals' Adderall XR, the leading ADHD drug, are up. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
The Motley Fool
October 8, 2007
Brian Lawler |
Noven's Acquisition Blues A recently acquired drug fails a late-stage clinical trial. Investors, take note. |
Pharmaceutical Executive
June 1, 2012 |
Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. |
BusinessWeek
October 27, 2003
Catherine Arnst |
Attention Deficit: Not Just Kid Stuff Drugmakers are starting to target an overlooked group: Adults with ADHD. |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
American Family Physician
November 1, 2000 |
When Adults Have ADHD Attention-deficit/hyperactivity disorder is also called ADHD. People with ADHD are hyperactive or distracted most of the time. Even when they try to concentrate, they find it hard to pay attention... |
American Family Physician
May 1, 2001 |
Learning About ADHD in Children ADHD, or attention-deficit/hyperactivity disorder, is a common health problem in children. Children with ADHD are hyperactive--they can't sit still. They are also impulsive and easily distracted. They have trouble coping at school and at home... |
